To hear about similar clinical trials, please enter your email below
Trial Title:
Pancreatic Cancer Initial Detection Via Liquid Biopsy
NCT ID:
NCT06283576
Condition:
Pancreatic Cancer
IPMN, Pancreatic
Individuals at Risk
Chronic Pancreatitis
Conditions: Official terms:
Pancreatic Neoplasms
Pancreatic Intraductal Neoplasms
Pancreatitis
Pancreatitis, Chronic
Conditions: Keywords:
diabetes mellitus
smoking
Study type:
Observational
Overall status:
Enrolling by invitation
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
Liquid biopsy
Description:
Blood will be drawn upon clinical diagnosis / prior to biopsy/surgical resection for
"ground truth"
Arm group label:
Healthy controls
Arm group label:
IPMN
Arm group label:
Pancreatic cancer, advanced
Arm group label:
Pancreatic cancer, early
Summary:
The overall rationale of PANCAID is to provide a diagnostic blood test for early
diagnosis of pancreatic cancer. With a set of different liquid biopsy methods, it is the
aim to measure these markers in well-defined patient cohorts. For the entire series of
these studies, the following groups are planned: 1) Histologically proven early-stage
pancreatic cancer (e.g. T1a/b and T2 carcinomas [N0M0]); 2) Intraductal papillary
mucinous neoplasia (IPMN) that were operated with verification of the benign,
premalignant or malignant histology; 3) ordinary branched-duct IPMN; 4) individuals at
risk (IAR) with and without IPMN, with and without known hereditary cancer gene (e.g.
BRCA2); 5) a high risk group of patients with chronic pancreatitis, aged 55-65, who are
heavy smokers (≥40 PY), with newly onset diabetes mellitus (NODM).
Criteria for eligibility:
Study pop:
Adults capable of giving informed consent to give blood for liquid biopsy coming to the
University Hospitals of Stockhol (Karolinska) and Umeå
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Suspicion of or elevated risk for pancreatic ductal adenocarcinoma (PDAC);
intraductal papillary mucinous neoplasias (IPMN); individuals at risk (IAR) for
pancreatic cancer
Exclusion Criteria:
- other malignant condition
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
Gastrocentrum, KarolinskaUniversity Hospital
Address:
City:
Stockholm
Zip:
14186
Country:
Sweden
Start date:
May 1, 2024
Completion date:
December 31, 2027
Lead sponsor:
Agency:
Karolinska University Hospital
Agency class:
Other
Collaborator:
Agency:
Umeå University
Agency class:
Other
Source:
Karolinska University Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06283576
